1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,210 | 1,260 | 10:55 | |
| 1,210 | 1,260 | 10:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | NanoViricides verlängert Verträge mit Führungskräften und passt Kreditlinie an | 2 | Investing.com Deutsch | ||
| 01.10. | NANOVIRICIDES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report | 570 | ACCESS Newswire | Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 29.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 8 | SEC Filings | ||
| 09.09. | NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 | 706 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 18.08. | NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials | 522 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 30.07. | Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides | 797 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 23.07. | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | 807 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 21.07. | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 868 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 16.07. | WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | 839 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 14.07. | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 938 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 01.07. | NanoViricides: There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | 708 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.06. | With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | 701 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the... ► Artikel lesen | |
| 04.06. | NanoViricides Measles Drug Development Animal Study is Imminent | 767 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 28.05. | NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | 1.096 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 22.05. | The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan | 952 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.The... ► Artikel lesen | |
| 16.05. | NanoViricides GAAP EPS of -$0.14 | 7 | Seeking Alpha | ||
| 16.05. | NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu | 1.008 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025... ► Artikel lesen | |
| 15.05. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.05. | NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | 996 | ACCESS Newswire | NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC)... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 25,250 | -0,20 % | ANLEIHEN-Woche KW40 - 2025: UBM, Eleving, reconcept, PCC, The Platform Group, Mutares, ABO Energy, Katjes Greenfood, PNE, Dautrus, The Grounds, Energiekontor, LEEF, WeGrow, Formycon, ESPG, Pferdewetten, … | Neuemissionen am KMU-Anleihemarkt Die Kalenderwoche steht im Zeichen neuer Anleiheemissionen - gleich mehrere Unternehmen haben den Markt mit frischen Angeboten adressiert, teils in Verbindung mit Umtauschangeboten... ► Artikel lesen | |
| ZENTEK | 0,660 | +2,33 % | Zentek Ltd.: Zentek Subsidiary Albany Graphite Corp. Provides Additional Positive Nuclear Suitability Testing Results | GUELPH, ON / ACCESS Newswire / October 6, 2025 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company, is pleased... ► Artikel lesen | |
| NVE | 59,50 | -2,46 % | Dividendenbekanntmachungen (04.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERIPRISE FINANCIAL INC US03076C1062 1,6 USD 1,3806 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,0258 EUR ATLANTIC UNION... ► Artikel lesen | |
| KOPIN | 2,892 | +3,95 % | Kopin Corporation Announces Agreement for $15 Million Strategic Investment From Theon International Plc to Accelerate Global Defense Innovation | Kopin gains significant access to the European and NATO defense market
Accelerates development of critical technologies
Further strengthens Kopin's balance sheet
Fixed conversion... ► Artikel lesen | |
| VEECO INSTRUMENTS | 25,800 | +0,78 % | Veeco Instruments stock downgraded by Northland on valuation concerns | ||
| GAUZY | 6,820 | 0,00 % | GAUZY LTD: Gauzy Debuts Its Next-Generation AI-Powered ADAS Technology for Buses, Smart-Vision CMS at Busworld 2025 | ||
| ONTO INNOVATION | 119,00 | 0,00 % | Jefferies stuft Onto Innovation auf "Buy" hoch: Erholung im CoWoS-Markt als Kurstreiber | ||
| FENDX TECHNOLOGIES | 0,570 | +5,56 % | FendX Technologies Inc.: FendX Advances Medical Catheter Coating Innovation: Provisional Patent Filed | Vancouver, British Columbia--(Newsfile Corp. - August 26, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTD) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| GOMSPACE | 1,258 | -1,10 % | GomSpace Extends Contract With A European Tech Firm For EUR 2.1 Mln, Stock Up | ||
| OBDUCAT | 0,025 | -3,85 % | NGM MARKET NOTICE: #25-43 Information regarding the last day of trading in paid subscribed shares issued by Obducat AB | ||
| ACACIA RESEARCH | 2,900 | +1,40 % | Acacia Research und Partner entwickeln eine mit Bitcoin gesicherte Gewerbedarlehensstrategie | ||
| ADVANCE ZINCTEK | 0,530 | 0,00 % | ADVANCE ZINCTEK LIMITED: Improvement of 26.83% in First Quarter Revenue - FY26 | ||
| LAMPETIA | 0,092 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,780 | 0,00 % | Nanofocus: Abfindungsangebot klar über aktuellem Kurs | Seit Ende Mai ist bekannt, dass die Carl Mahr Holding Nanofocus übernehmen will. Jetzt wird die Sache sehr konkret. Die Gesellschaft aus Göttingen legt ein konkretisiertes Squeeze-Out-Verlangen vor.... ► Artikel lesen | |
| RIBER | 3,265 | +1,24 % | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook. Half-year revenues and earnings, particularly marked by seasonal activity patterns. Order book of €27.7m... ► Artikel lesen |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.